Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
Por:
Baptista, MJ, Tapia, G, Munoz-Marmol, AM, Muncunill, J, Garcia, O, Montoto, S, Gribben, JG, Calaminici, M, Martinez, A, Veloza, L, Martinez-Trillos, A, Aldamiz, T, Menarguez, J, Terol, MJ, Ferrandez, A, Alcoceba, M, Briones, J, Gonzalez-Barca, E, Climent, F, Muntanola, A, Moraleda, JM, Provencio, M, Abrisqueta, P, Abella, E, Colomo, L, Garcia-Ballesteros, C, Garcia-Caro, M, Sancho, JM, Ribera, JM, Mate, JL and Navarro, JT
Publicada:
1 dic 2022
Ahead of Print:
1 oct 2022
Resumen:
The frequency of aggressive subtypes of B-cell non-Hodgkin lymphoma (B-NHL), such as high-grade B-cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH/TH) or Burkitt-like lymphoma (BL) with 11q aberration, is not well known in the HIV setting. We aimed to characterise HIV-associated aggressive B-NHL according to the 2017 WHO criteria, and to identify genotypic and phenotypic features with prognostic impact. Seventy-five HIV-associated aggressive B-NHL were studied by immunohistochemistry (CD10, BCL2, BCL6, MUM1, MYC, and CD30), EBV-encoded RNAs (EBERs), and fluorescence in situ hybridisation (FISH) to evaluate the status of the MYC, BCL2, and BCL6 genes and chromosome 11q. The 2017 WHO classification criteria and the Hans algorithm, for the cell-of-origin classification of diffuse large B-cell lymphomas (DLBCL), were applied. In DLBCL cases, the frequencies of MYC and BCL6 rearrangements (14.9 and 27.7%, respectively) were similar to those described in HIV-negative patients, but BCL2 rearrangements were infrequent (4.3%). MYC expression was identified in 23.4% of DLBCL cases, and coexpression of MYC and BCL2 in 13.0%, which was associated with a worse prognosis. As for BL cases, the expression of MUM1 (30.4%) conferred a worse prognosis. Finally, the prevalence of HGBL-DH/TH and BL-like with 11q aberration are reported in the HIV setting. The phenotypic and genotypic characteristics of HIV-associated aggressive B-NHL are similar to those of the general population, except for the low frequency of BCL2 rearrangements in DLBCL. MYC and BCL2 coexpression in DLBCL, and MUM-1 expression in BL, have a negative prognostic impact on HIV-infected individuals.
Filiaciones:
:
Univ Autonoma Barcelona, Dept Hematol, ICO Germans Trias & Pujol Hosp, Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain
:
Univ Autonoma Barcelona, Dept Pathol, Hosp Germans Trias & Pujol, IGTP, Badalona, Spain
:
Univ Autonoma Barcelona, Dept Pathol, Hosp Germans Trias & Pujol, IGTP, Badalona, Spain
Muncunill, J:
Univ Autonoma Barcelona, Dept Hematol, ICO Germans Trias & Pujol Hosp, Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain
Garcia, O:
Univ Autonoma Barcelona, Dept Hematol, ICO Germans Trias & Pujol Hosp, Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain
Montoto, S:
Queen Mary Univ London, Ctr Haematooncol, Barts Canc Inst, London, England
Gribben, JG:
Queen Mary Univ London, Ctr Haematooncol, Barts Canc Inst, London, England
Calaminici, M:
Queen Mary Univ London, Ctr Haematooncol, Barts Canc Inst, London, England
Martinez, A:
Univ Barcelona, Dept Pathol, Hosp Clin, IDIBAPS, Barcelona, Spain
Veloza, L:
Univ Barcelona, Dept Pathol, Hosp Clin, IDIBAPS, Barcelona, Spain
Martinez-Trillos, A:
Univ Barcelona, Dept Hematol, Hosp Clin, IDIBAPS, Barcelona, Spain
Aldamiz, T:
Hosp Gregorio Maranon, Dept Infect Dis, Madrid, Spain
Menarguez, J:
Hosp Gregorio Maranon, Dept Pathol, Madrid, Spain
Terol, MJ:
Hosp Clin Univ Valencia, Dept Hematol & Oncol, Valencia, Spain
Ferrandez, A:
Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain
Alcoceba, M:
Hosp Univ Salamanca HUS IBSAL, CIBERONC, Dept Hematol, Salamanca, Spain
Ctr Invest Crincer IBMCC USAL CSIC, Salamanca, Spain
Briones, J:
Hosp Santa Creu & Sant Pau, Josep Carreras Leukaemia Res Inst IJC, Dept Hematol, Barcelona, Spain
Gonzalez-Barca, E:
ICO Hosp Duran & Reynals, Dept Hematol, Lhospitalet De Llobregat, Spain
Climent, F:
Hosp Univ Bellvitge IDIBELL, Dept Pathol, Badalona, Spain
Muntanola, A:
Hosp Univ Mutua Terrassa, Dept Clin Hematol, Terrassa, Spain
Moraleda, JM:
Hosp Clin Univ Virgen de la Arrixaca, Dept Hematol, Murcia, Spain
Provencio, M:
Hosp Univ Puerta Hierro, Dept Med Oncol, Majadahonda, Spain
Abrisqueta, P:
Hosp Valle De Hebron, Dept Hematol, Barcelona, Spain
Abella, E:
Hosp del Mar, Dept Hematol, Barcelona, Spain
Colomo, L:
Hosp del Mar, Dept Pathol, Barcelona, Spain
Garcia-Ballesteros, C:
Hosp Arnau Vilanova, Dept Hematol, Valencia, Spain
Garcia-Caro, M:
Hosp Mataro, Dept Hematol, Barcelona, Spain
:
Univ Autonoma Barcelona, Dept Hematol, ICO Germans Trias & Pujol Hosp, Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain
:
Univ Autonoma Barcelona, Dept Hematol, ICO Germans Trias & Pujol Hosp, Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain
:
Univ Autonoma Barcelona, Dept Pathol, Hosp Germans Trias & Pujol, IGTP, Badalona, Spain
:
Univ Autonoma Barcelona, Dept Hematol, ICO Germans Trias & Pujol Hosp, Josep Carreras Leukaemia Res Inst IJC, Badalona, Spain
hybrid
|